FDA to Research Ibogaine and Taboo Psychedelics Following Joe Rogan’s Influence

President Donald Trump has signed an executive order directing the U.S. Food and Drug Administration to expedite research into ibogaine and other psychedelic substances for the treatment of post-traumatic stress disorder, according to a report by Rolling Stone published on April 18, 2026.

The order follows a text message from podcast host Joe Rogan, who attended the Oval Office signing ceremony, informing the president of potential therapeutic benefits associated with psychedelics in addressing trauma-related conditions. Rogan has previously discussed ibogaine and similar compounds on his podcast, advocating for expanded scientific investigation into their use for mental health disorders.

The executive action aims to reduce bureaucratic barriers that have historically delayed clinical trials involving Schedule I substances, which include ibogaine, psilocybin, and MDMA under current federal classification. By instructing the FDA to prioritize and accelerate evaluation processes, the administration seeks to facilitate faster pathways for investigational new drug applications and early-phase clinical studies focused on veterans and first responders suffering from PTSD.

Context on Psychedelic Research and Federal Policy

For decades, psychedelic substances have been classified as having no accepted medical use and a high potential for abuse under the Controlled Substances Act, severely limiting domestic research opportunities. However, growing evidence from international studies and early-phase U.S. Trials has suggested potential therapeutic value in treating treatment-resistant depression, anxiety, and PTSD when administered in controlled clinical settings.

FDA’s Role and Expected Next Steps

The FDA’s involvement under the order will focus on streamlining regulatory review, providing guidance to researchers, and coordinating with the National Institutes of Health and the Department of Veterans Affairs to identify priority areas for investigation. While the order does not approve any substance for medical use or alter its legal status, it signals a shift toward evaluating psychedelics through an evidence-based framework rather than categorical restriction.

Reactions and Broader Implications

Supporters of psychedelic reform have welcomed the directive as a long-overdue step toward aligning federal policy with emerging scientific data. Organizations such as the Multidisciplinary Association for Psychedelic Studies (MAPS) and the U.S. Veterans Administration have previously called for expanded access to investigational therapies, particularly for populations disproportionately affected by trauma.

Critics caution that expedited review must not compromise safety standards, emphasizing the need for rigorous clinical protocols, informed consent procedures, and long-term follow-up studies to assess both efficacy and risks. The order does not allocate specific funding for research, leaving financial support to depend on existing grant mechanisms, private investment, or future congressional action.

As of the date of the report, the White House had not released the full text of the executive order, and the FDA had not issued a public statement detailing its implementation plan. The development adds to a series of recent federal actions reflecting renewed interest in psychedelic science, including congressional hearings and NIH-funded studies exploring novel mental health interventions.